Table 2.

Role of m6A regulator in targeted therapy

Drug	Regulator	Role	Level	Cancer	Target	Effect	Refs.
Sorafenib	METTL3	Oncogene	High	HCC	DUXAP8	Increases DUXAP8 RNA stability	[102]
Sorafenib	METTL3	Oncogene	High	HCC	NIFK-AS1	Upregulates NIFK-AS1 expression	[103]
Sorafenib	METTL3/14	Oncogene	High	HCC	SORE	Increases stability of SORE	[104]
Sorafenib	METTL3	Suppressor	Low	HCC	FOXO3	Stabilizes FOXO3 mRNA by YTHDF1	[105]
Sorafenib	METTL14	Suppressor	Low	HCC	HNF3γ	Increases HNF3γ mRNA stability via IGF2BPs	[106]
Sorafenib	RBM15B	Oncogene	High	HCC	TRAM2	Increases stability of TRAM2 mRNA	[107]
Gefitinib	METTL3	Oncogene	High	LUAD	lncRNA SNHG17	Increases SNHG17 RNA stability	[108]
Gefitinib	METTL3	Oncogene	High	LUAD	ATG5, ATG7	Upregulates expression of ATG5, ATG7	[109]
Gefitinib	KIAA1429	Oncogene	High	NSCLC	HOXA1	Increases HOXA1 mRNA stability	[110]
Gefitinib	FTO	Oncogene	High	NSCLC	ABCC10	Reduces the YTHDF2-mediated degradation of ABCB10	[111]
Gefitinib	FTO	Oncogene	High	NSCLC	MYC	promotes MYC expression	[112]
Erlotinib	YTHDF2	Oncogene	NA	LC	TUSC7	Promotes the degradation of TUSC7	[113]
Osimertinib	METTL3	Suppressor	Low	LUAD	Let-7b	Promotes the pri-Let-7b maturation via HNRNPA2B1	[114]
cetuximab	hnRNPA2B1	Oncogene	NA	CRC	TCF7L2	Increases stability of TCF7L2 mRNA	[115]
Cetuximab	METTL3	Oncogene	High	CRC	miR-100 and miR-125b	Reduces the miR-100 and miR-125b level and export	[116]
apatinib	METTL3	Oncogene	NA	GC	P53	Suppresses p53 activation	[117]
sunitinib	METTL14	Oncogene	NA	RCC	TRAF1	Increases TRAM1 mRNA stability via IGF2BP2	[118]
PLX4032	METTL3	Oncogene	NA	Melanoma	EGFR	Promotes translation of EGFR	[119]
crizotinib	METTL3, WTAP	Oncogene	NA	NSCLC	c-MET	Decrease expression of c-MET	[120]
Olaparib and Rucaparib	FTO, ALKBH5	Suppressor	Low		FZD10	Suppresses IGF2BP2-mediated stabilization of FZD10 mRNA	[121]